<DOC>
	<DOCNO>NCT00843986</DOCNO>
	<brief_summary>This study evaluate safety effectiveness Conivaptan , vasopressin antagonist , treatment hyponatremic subject symptomatic acute decompensated heart failure ( ADHF ) .</brief_summary>
	<brief_title>Safety Efficacy Conivaptan Hyponatremic Patients With Symptomatic Acute Decompensated Heart Failure ( ADHF )</brief_title>
	<detailed_description>Subjects recruit Emergency Department . It expect subject treat accord institution 's accepted conventional therapy protocol treatment ADHF . Therapy may also include use loop diuretic relief pulmonary congestion maintenance adequate urine output .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Hyponatremia</mesh_term>
	<mesh_term>Conivaptan</mesh_term>
	<criteria>Presents emergency department document history CHF symptomatic ADHF , treat ADHF , primary reason admission hospital ADHF Dyspnea rest minimal exertion must moderate shortness breath ( SOB ) first three Provocative Dyspnea Assessment position Severe pulmonary congestion evidence jugular venous distention lower extremity/sacral edema rale upon chest auscultation chest xray . BNP &gt; 400 NTpro BNP &gt; 1500 drawn Screening Systolic blood pressure &gt; = 100 mmHg &lt; 180 mmHg time start study drug Serum sodium value &gt; = 115 mEq/L ( 115 mmol/L ) &lt; 135 mEq/L ( 135 mmol/L ) Screening Clinical evidence volume depletion Active ongoing acute coronary syndrome acute ST segment elevation myocardial infarction ( experienced myocardial infarction within 30 day Screening ) In cardiogenic shock Calculated creatinine clearance &lt; 30 mL/min/1.73 m2 estimate Modification Diet Renal Disease ( MDRD ) equation , receive intravenous ( IV ) contrast agent within 72 hour prior randomization expect receive IV contrast agent within first 72 hour study participation Ultrafiltration within past 72 hour . Currently use expect use inotropic therapy Cardiac bypass graft past 60 day Cerebrovascular accident past 30 day Uncontrolled brady ventricular tachyarrhythmias require emergent pacemaker placement treatment Hemodynamically significant uncorrected primary cardiac valvular disease hypertrophic cardiomyopathy Untreated severe hypothyroidism , hyperthyroidism adrenal insufficiency base medical history ALT AST elevation &gt; 5 time upper limit normal Biliary liver cirrhosis , history presence severe hepatic encephalopathy , ascites , esophageal variceal bleeding within past three month , severe portal hypertension surgical portosystemic shunt . Received organ transplant , clinical diagnosis pneumonia , symptomatic hyponatremia require urgent intervention concurrent illness , opinion investigator , may interfere treatment evaluation safety Pregnant lactate Currently use vasopressin , oxytocin desmopressin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>hyponatremia</keyword>
	<keyword>euvolemic hyponatremia</keyword>
	<keyword>hypervolemic hyponatremia</keyword>
	<keyword>acute decompensated heart failure</keyword>
	<keyword>conivaptan</keyword>
	<keyword>Vaprisol</keyword>
</DOC>